GSK touts lung cancer data from two drugs

FDA panel confronting peptide controversy You’re reading STAT’s Readout newsletter https://www.statnews.com/2026/07/23/health-policy-news-today-dc-diagnosis-newsletter-john-wilkerson-2/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-9kun-OCNmvZQs8LoxJp32FSuPqRJn05k9v-0ZsLjsEQiI7XSH6Fn5uS6A6Fw9Spy_f358tO9JeqEfL3EsL6r_ZS6-Itw&_hsmi=438904019&utm_content=438904019&utm_source=hs_email GSK touts lung cancer data from two drugs GSK plans to ask the FDA to expand the approval of its lung cancer drug Jideytro after presenting new data showing the targeted therapy produced durable responses in the majority of patients. The FDA authorized Jideytro in July for patients with non-small cell lung cancer with an ROS1 mutation who had already had been treated with a tyrosine kinase inhibitor. The new data came from a study of Jideytro as a first-line therapy. The ARROS-1 trial saw a 94% objective response rate, with the median duration of response and median progression-free survival not yet reached at the cutoff point, according to data presented at the World Conference on Lung Cancer in Seoul. The drug also helped shrink brain metastases in patients whose cancer had spread. GSK picked up Jideytro, known as zidesamtinib, through its acquisition of Nuvalent, as the U.K. firm has stepped up its return to oncology. Also at WCLC, Hansoh Pharmaceutical Group detailed strong data for the ADC ris-rez in a form of difficult-to-treat small cell lung cancer, showing that it reduced the risk of death as a second-line treatment. GSK has licensed global rights for ris-rez rights. Hansoh’s study took place in China, and there are outstanding questions about how instructive data from trials that solely take place in China are for the results of global trials that will be required by regulators in other parts of the world. But analysts say the ris-rez data released so far are promising for the medicine’s prospects. “We're really starting to see the emergence of what is probably the start of a franchise for GSK oncology and lung cancer,” Hesham Abdullah, the head of GSK’s oncology R&D, told reporters. Nuvalent says its ROS1-targeted drug shrank lung tumors in patients who failed other options The company hopes its non-small cell lung cancer drug will be used where predecessors have not https://www.statnews.com/2025/06/24/nuvalent-lung-cancer-ros1-zidesamtinib/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-8Tsobhw9kX8rfiH8Xp9IEw_Or-xLam8Wv4W6WcPaHX5e8012fIknDwOImDheKv0My2pqUXDFMxhQN3kK04_c7azx8WfA&_hsmi=438904019&utm_content=438904019&utm_source=hs_email GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B The move will grow the U.K. firm’s work in oncology, particularly in lung cancer https://www.statnews.com/2026/06/09/gsk-nuvalent-acquistion-oncology-lung-cancer-zidesamtinib-neladalkib/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-_X6Y6EM22y3LdsAlam5G8LKiGBX4COyFF-BN1HagJu2H_X58_wFgF1pm80CWuKXI4QzRJldmRZXXVzkPkdH_e1Ly0K6g&_hsmi=438904019&utm_content=438904019&utm_source=hs_email